Hepatocellular carcinoma
Conditions
Interventions
Observation group:None
Sponsors
Affiliated Hospital of Nantong University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.The subjects voluntarily joined this study and signed the informed consent form. 2.Age ranging from 18 to 75 years old, gender not limited; 3.Patients with clinically diagnosed hepatocellular carcinoma and those with hepatocellular carcinoma pathologically confirmed by puncture biopsy (the clinical diagnosis of hepatocellular carcinoma is based on the "Diagnosis and Treatment Guidelines for Primary Liver Cancer 2024"), with CNLC stage II or III or BCLC stage B or C; 4.Patients with ECOG-PS scores of 0-2, no severe autoimmune diseases, severe comorbidities or other contraindications to immunotherapy; 5.Imaging can evaluate the lesion. According to the efficacy evaluation criteria for Solid Tumors (RECIST version 1.1), there is at least one single-diameter measurable lesion.
Exclusion criteria
Exclusion criteria: 1.There are other malignant diseases requiring systematic treatment (except for cured basal cell carcinoma of the skin or carcinoma in situ of the cervix). 2.Have a history of other malignant tumors within the past 6 months (except as above) 3.Severe autoimmune diseases or the need for long-term use of immunosuppressants 4.Difficult-to-control infections (body temperature >=38? or uncontrolled infectious diseases) 5.Severe systemic diseases (such as uncontrolled heart disease, diabetes) 6.Pathological tissues could not be obtained or the construction of the PDOTS model failed 7.Have received PD-1/PD-L1 antibody treatment (including tislelizumab) previously 8.Allergic to tislelizumab or the ingredients of the investigational drug 9.Pregnant or lactating women 10.Uncontrollable mental illness affects compliance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Organoid killing index;Objective Response Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Progression free survival; | — |
Countries
China
Contacts
Public ContactZhong Chen
Affiliated Hospital of Nantong University
Outcome results
None listed